| Literature DB >> 31165776 |
George Cholankeril1, Andrew A Li2, Brittany B Dennis3, Chiranjeevi Gadiparthi4, Donghee Kim1, Alice E Toll5, Benedict J Maliakkal4, Sanjaya K Satapathy4, Satheesh Nair4, Aijaz Ahmed6.
Abstract
Clinical decompensation immediately prior to liver transplantation may affect post-liver transplant (LT) outcomes. Using the serial Model for End-Stage Liver Disease (MELD) scores recorded in the United Network for Organ Sharing national registry (2010-2017), we analyzed post-LT mortality among adult LT recipients based on the degree of fluctuation in MELD score during the 30-day period prior to LT surgery. Delta-MELD (D-MELD) was defined as recipient MELD score at LT minus lowest MELD score within the preceding 30 days. Impact of D-MELD as a continuous and categorical variable (D-MELD 0-4, 5-10, >10) on early, 30-day post-LT mortality was assessed. Overall, a total of 12,785 LT recipients were analyzed, of which 8,862 (67.9%) had a pre-operative D-MELD 0-4; 2,574 (20.1%) with a D-MELD 5-10; and 1,529 (12.0%) with a D-MELD > 10. One-point incremental increase in pre-operative D-MELD (adjusted HR, 1.07, 95% CI: 1.04-1.10) was associated with higher 30-day post-LT mortality. Moreover, pre-operative D-MELD > 10 was associated with nearly a two-fold increased risk for 30-day post-LT mortality (adjusted HR, 1.89, 95% CI: 1.30-2.77) compared to D-MELD 0-4. The increased risk of pre-LT mortality associated with severity of clinical decompensation assessed by the magnitude of pre-operative D-MELD persists in the early post-LT period.Entities:
Mesh:
Year: 2019 PMID: 31165776 PMCID: PMC6549161 DOI: 10.1038/s41598-019-44814-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Study identification, inclusion, and exclusion criteria utilized in constructing D-MELD cohorts.
Clinical characteristics of liver transplant recipients categorized by D-MELD.
| Total Cohort (n = 12,785) | D-MELD 0–4 (n = 8,862) | D-MELD 5–10 (n = 2,574) | D-MELD > 10 (n = 1,529) | ||
|---|---|---|---|---|---|
| 55 (48–61) | 55 (48–61) | 56 (49–62) | 57(50–62) | 0.1528 | |
|
| 8239 (64.4) | 5726 (64.6) | 1591 (61.8) | 922(60.3) | 0.3372 |
|
| |||||
| Caucasian | 9058 (70.8) | 6180 (71.2) | 1830 (71.1) | 1048 (68.5) | 0.0029 |
| Black | 1363 (10.7) | 1002 (11.5) | 246 (9.6) | 115 (7.5%) | |
| Hispanic | 1833 (14.3) | 1153 (13.3) | 386 (15.0) | 294 (19.2) | |
| Asian | 352 (2.8) | 230 (2.6) | 74 (2.9) | 48 (3.1) | |
|
| |||||
| ALD | 2885 (22.6) | 2109 (24.3) | 520 (20.2) | 256 (16.7) | 0.0002 |
| HCV | 3076 (24.1) | 1994 (22.5) | 632 (24.6) | 450 (29.4) | |
| ALD/HCV | 652 (5.1) | 442 (5.1) | 121 (4.7) | 89 (5.8) | |
| NASH | 1941 (15.2) | 1342 (15.5) | 397 (15.4) | 202 (13.2) | |
| Cholestatic Liver Disease | 1342 (10.5) | 851 (9.8) | 292 (11.3) | 199 (13.0) | |
| Other | 2889 (22.6) | 1944 (22.4) | 612 (23.8) | 333 (21.8) | |
|
| 1.36 (1.12, 1.65) | 1.36 (1.12, 1.65) | 1.35 (1.12, 1.62) | 1.34 (1.13, 1.63) | 0.8350 |
|
| 588 (4.6) | 442 (5.3) | 104 (4.1) | 42 (2.8) | 0.0258 |
|
| 3652 (28.6) | 2300 (26.5) | 639 (24.8) | 713 (46.6) | <0.0001 |
|
| 11151 (87.2) | 7489 (86.3) | 2263 (87.9) | 1399 (91.5) | 0.0004 |
|
| 2052 (16.1) | 1234 (14.2) | 455 (17.7) | 363 (23.7) | <0.0001 |
ALD, alcoholic liver disease, D-MELD, delta change in Model for End-Stage Liver Disease score; HCV, chronic hepatitis C virus infection; INR, international normalized ratio for prothrombin time; IQR, interquartile range; NASH, nonalcoholic steatohepatitis.
Study cohort MELD scores and differences in MELD score parameters.
| Total Cohort | D-MELD 0–4 (n = 8,862) | D-MELD 5–10 (n = 2,574) | D-MELD > 10 (n = 1,529) | ||
|---|---|---|---|---|---|
| Median Lowest MELD (IQR) | 25 (21–32) | 26 (21–36) | 26 (22–30) | 23 (20–26) | <0.0001 |
| Median MELD score at Transplant (IQR) | 31 (24–39) | 27 (23–37) | 33 (29–39) | 40 (36–40) | <0.0001 |
| Median D-MELD (IQR) | 2 (0–6) | 1 (0–2) | 7 (5–8) | 14 (12–17) | <0.0001 |
| Mean Change in Creatinine (SD) | 0.23 (1.06) | 0.01 (0.85) | 0.49 (1.04) | 1.18 (1.51) | <0.0001 |
| Mean Change in Sodium (SD) | 0.40 (5.0) | 0.09 (3.81) | 0.52 (6.26) | 1.95 (7.50) | <0.0001 |
| Mean Change in Bilirubin (SD) | 2.83 (7.00) | 0.97 (3.93) | 4.21 (7.12) | 11.23 (12.05) | <0.0001 |
| Mean Change in INR (SD) | 0.42 (1.80) | 0.14 (1.19) | 0.74 (2.35) | 1.42 (2.86) | <0.0001 |
D-MELD, delta change in Model for End-Stage Liver Disease score; INR, international normalized ratio for prothrombin time; IQR, interquartile range; MELD, Model for End-Stage Liver Disease score; SD, standard deviation.
Figure 2Cumulative incidence post-transplant mortality curves in cohorts with pre-operative D-MELD < 5 (0–4), D-MELD 5–10 and D-MELD > 10 taking the competing risk of graft failure and re-transplantation into account.
Univariate and multivariate Cox regression models analyzing D-MELD as a continuous and categorical variable on early post-transplant mortality.
| Univariate HR (95% CI) | Multivariate HRa (95% CI) | |||
|---|---|---|---|---|
|
| ||||
| 7-Day | 1.03 (1.01–1.05) | 0.0122 | 1.07 (1.02–1.12) | 0.002 |
| 30-Day | 1.04 (1.02–1.06) | <0.001 | 1.07 (1.04–1.10) | <0.001 |
| 1-Year | 1.03 (1.02–1.04) | <0.001 | 1.04 (1.02–1.05) | <0.001 |
|
| ||||
| D-MELD 0–4 | Reference | Reference | ||
| D-MELD 5–10 | 1.38 (1.02–1.88) | 0.0388 | 1.40 (0.99–2.00) | 0.0600 |
| D-MELD > 10 | 1.43 (1.05–2.07) | 0.0484 | 1.82 (1.09–3.06) | 0.0266 |
|
| ||||
| D-MELD 0–4 | Reference | Reference | ||
| D-MELD 5–10 | 1.38 (1.10–1.66) | <0.001 | 1.34 (1.03–1.76) | 0.0316 |
| D-MELD > 10 | 1.92 (1.45–2.39) | <0.001 | 1.89 (1.30–2.77) | 0.0010 |
|
| ||||
| D-MELD 0–4 | Reference | Reference | ||
| D-MELD 5–10 | 1.32 (1.16–1.51) | <0.001 | 1.31 (1.13–1.52) | <0.001 |
| D-MELD > 10 | 1.40 (1.20–1.64) | <0.001 | 1.33 (1.06–1.67) | 0.0131 |
CI, confidence interval D-MELD, delta change in Model for End-Stage Liver Disease Score; HR, hazard ratio.
aMultivariate analysis adjusted for recipient age, gender, ethnicity, etiology of liver disease, liver donor risk index, donation after cardiac death, renal dialysis, ascites, hepatic encephalopathy, MELD score at transplant, mean change in MELD score parameters (sodium, creatinine, bilirubin, INR) and UNOS Region.
bD-MELD analyzed as a continuous variable with one-point increments.
Multivariate Cox regression analyses to predict risk factors for 30-day post-transplant mortality.
| HRa (95% CI) | ||
|---|---|---|
|
| 1.03 (1.02–1.04) | <0.0001 |
|
| 1.09 (0.87–1.35) | 0.4589 |
|
| ||
| Caucasian | Reference | |
| African-American | 0.91 (0.63–1.31) | 0.6058 |
| Hispanic | 1.03 (0.76–1.40) | 0.8337 |
| Asian | 1.28 (0.75–2.19) | 0.3669 |
|
| ||
| ALD | Reference | |
| HCV | 0.97 (0.71–1.33) | 0.8575 |
| NASH | 1.05 (0.74–1.48) | 0.7924 |
| Cholestatic Liver Disease | 1.16 (0.68–1.97) | 0.5876 |
|
| 1.67 (1.09–2.54) | 0.0180 |
|
| 1.40 (1.21–1.60) | <0.0001 |
|
| 1.37 (1.08–1.75) | 0.0099 |
|
| 1.19 (0.81–1.74) | 0.3712 |
|
| 1.16 (0.84–1.61) | 0.3667 |
|
| ||
| D-MELD < 5 (0–4) | Reference | |
| D-MELD 5–10 | 1.34 (1.03–1.76) | 0.0316 |
| D-MELD > 10 | 1.89 (1.30–2.77) | 0.0010 |
ALD, alcoholic liver disease; CI, confidence interval D-MELD, delta change in Model for End-Stage Liver Disease Score; HCV, chronic hepatitis C virus infection; HR, hazard ratio; NASH, nonalcoholic steatohepatitis.
aAdditionally adjusted for recipient MELD score at transplant, change in MELD score parameters (sodium, creatinine, bilirubin, international normalized ratio) and UNOS Region.